Skip to main content
. 2022 Oct 30;129(1):71–81. doi: 10.1002/cncr.34512

FIGURE 1.

FIGURE 1

Change in target lesion from baseline (best response) in CPI‐naïve patients enrolled in phase 2 of the study. BID indicates twice daily; CPI, checkpoint inhibitor; NSCLC, non–small cell lung cancer; PD‐L1, programmed death ligand‐1; SCCHN, squamous cell carcinoma of the head and neck; TNBC, triple‐negative breast cancer.